BTIG reaffirms its Buy rating and $9 price target on NeoGenomics Inc. (Nasdaq: NEO) following Q4 results and outlook issued yesterday morning.

Analyst Sean Lavin noted that FY16 guidance was largely inline with prior expectations. Commentary around initial integration efforts was encouraging, and we think upside is possible through the course of the year via successful cross-selling, new contract wins and CRO testing ramping better than expectations, the analyst noted.

Lavin was also positive on integration progress, stating, We are generally focused on the potential for revenue attrition (typically seen in lab M&A); in the past, NEO has suggested that its guidance has factored in ~$6M in overall share loss for 2016. Mgmt commented that it has not seen deal-related share loss this early on, which we find encouraging.

For an analyst ratings summary and ratings history on Neogenomics click here. For more ratings news on Neogenomics click here.